Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wave Life Sciences Ltd. (Nasdaq: WVE) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed through EDGAR. Wave is a clinical-stage biotechnology company incorporated in Singapore with ordinary shares listed on The Nasdaq Global Market, and it uses SEC filings to report material events, financial results, securities offerings, and corporate actions.
Recent WVE SEC filings include multiple Forms 8-K describing public offerings of ordinary shares and pre-funded warrants under an automatically effective shelf registration statement on Form S-3ASR, along with related underwriting agreements and legal opinions. Other 8-K filings furnish press releases covering quarterly financial results, clinical data updates for programs such as WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, and corporate presentations made available to investors.
Wave also files 8-Ks to report shareholder meeting outcomes and compensation-related matters, such as amendments to its equity incentive plan and voting results from its annual general meeting. Many of these filings specify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and indicate when press releases or slide decks are incorporated by reference.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items like new securities offerings, changes to compensation plans, or important clinical and financial announcements referenced in 8-Ks. Users can review filing titles, dates, and summarized content, then open the full SEC documents for detailed analysis of Wave Life Sciences’ regulatory and disclosure history.
Wave Life Sciences reported first-quarter 2026 revenue of $38.2M, up from $9.2M a year earlier, mainly from its GSK collaboration, including recognition of remaining deferred revenue after regaining full rights to AATD candidate WVE-006.
Operating expenses rose to $69.5M, but the operating loss narrowed to $31.3M, and net loss improved to $26.1M or $0.13 per share, compared with a $46.9M loss or $0.29 per share a year ago.
Wave ended the quarter with $544.6M in cash and cash equivalents and expects this to fund operations for at least 12 months. The company highlighted progress across its RNA programs, including obesity candidate WVE-007, RNA editing programs WVE-006 and WVE-008, DMD therapy WVE-N531, and HD candidate WVE-003, and outlined plans to redomicile its parent entity from Singapore to Delaware.
Wave Life Sciences reported first quarter 2026 results and a broad pipeline update. Revenue rose to $38.2 million from $9.2 million a year earlier, while net loss narrowed to $26.1 million, or $0.13 per share, from $46.9 million.
Cash and cash equivalents were $544.6 million as of March 31, 2026, with an expected cash runway into the third quarter of 2028. The company highlighted progress for obesity candidate WVE-007, RNA editing program WVE-006 for AATD, liver disease program WVE-008, and exon 53 Duchenne therapy WVE-N531, with multiple data readouts and regulatory milestones targeted in 2026.
Wave Life Sciences Ltd. reported that its proposed redomiciliation of the group’s parent company from Singapore to the United States is progressing through the Singapore court process. The company has applied to the Singapore High Court to convene a shareholder meeting to vote on a Scheme of Arrangement under Section 210 of the Companies Act 1967.
The application, filed as case HC/OA 434/2026, is scheduled to be heard on April 29, 2026 at 10:00 am (Singapore Time). The court has set deadlines of 4:00 pm on April 22, 2026 for affidavits and 4:00 pm on April 24, 2026 for written submissions and bundles of authorities. The redomiciliation remains subject to approval by Wave shareholders and the Singapore High Court, and a definitive proxy statement with detailed information will be filed with the SEC and mailed or otherwise disseminated to shareholders.
Wave Life Sciences Ltd. Chief Medical Officer Christopher I. Wright filed an initial ownership report showing his equity position. He holds options over 300,000 ordinary shares at an exercise price of $5.94 expiring on May 27, 2035 and options over 273,750 ordinary shares at $12.75 expiring on February 5, 2036, all held directly. He also directly owns 45,625 ordinary shares. Footnotes explain that these options and restricted share units vest in stages between May 27, 2026 and February 8, 2030, contingent on his continued service with the company.
Wave Life Sciences Ltd. Chief Scientific Officer Erik Ingelsson filed an initial ownership report showing his current equity position in the company. He directly holds 87,864 ordinary shares, including 17,489 shares and time-based RSUs that vest in annual installments from February 8, 2027 through February 8, 2030, subject to his continued service.
Ingelsson also holds three option awards to purchase ordinary shares: 350,000 shares at an exercise price of $5.85 expiring on May 8, 2034; 200,000 shares at $11.74 expiring on February 4, 2035; and 273,750 shares at $12.75 expiring on February 5, 2036. Each option vests over several years, with 25% vesting on an initial date and the remainder vesting quarterly, conditioned on continued service.
RA Capital Management and related parties report owning 34,225,506 ordinary shares of Wave Life Sciences Ltd., representing 17.1% of the company’s ordinary shares outstanding. Their holdings include shares held by RA Capital Healthcare Fund, pre-funded warrants that are immediately exercisable, and options held by Peter Kolchinsky for RA Capital’s benefit.
The group reports shared voting and dispositive power over these securities and disclaims beneficial ownership beyond Section 13(d) reporting purposes. The amendment also notes that Wave Life Sciences Ltd. entered into an Implementation Agreement for a Singapore-law Scheme of Arrangement to redomicile into a new Delaware corporation, Wave Life Sciences, Inc., with a one-for-one share exchange, subject to shareholder and Singapore court approval.
Wave Life Sciences Ltd. is asking shareholders to approve a Scheme of Arrangement to redomicile the parent from Singapore to a newly formed Delaware corporation, Wave Life Sciences, Inc. under an Implementation Agreement dated April 15, 2026. Under the Scheme, each Wave-Singapore ordinary share will be exchanged one-for-one for Wave-Delaware common stock, which the company intends to list on Nasdaq under the symbol WVE. The Scheme requires shareholder approval (a majority in number and at least 75% of votes cast by value) and sanction by the Singapore High Court; if approved and conditions satisfied, the court order will be lodged with ACRA and the Scheme will become effective. The board unanimously recommends a vote FOR the Wave Redomiciliation Proposal. The proxy statement discusses differences in shareholder rights under Delaware law, potential tax and stamp duty considerations (including a Singapore stamp duty rate of 0.2%), and expected U.S. GAAP accounting as a common-control reorganization.
Wave Life Sciences Ltd. plans to move its parent company domicile from Singapore to Delaware through a court-approved redomiciliation. Under a Singapore law scheme of arrangement, each existing Wave-Singapore ordinary share will be exchanged on a one-for-one basis for common stock of a new Delaware parent, Wave Life Sciences, Inc.
The new Delaware parent is expected to become the group’s ultimate holding company in mid-2026, subject to shareholder and Singapore High Court approvals, while continuing to operate the business substantially as before. The stock will keep trading on the Nasdaq Global Market under the symbol WVE, with reporting in U.S. dollars under U.S. GAAP, and the redomiciliation is expected to be tax-free to U.S. shareholders.
RA Capital and affiliates report a larger stake in Wave Life Sciences Ltd., now beneficially owning 34,225,506 ordinary shares, or 17.5% of the company’s outstanding shares. The ownership is reported across RA Capital Management, its healthcare fund, and managers Peter Kolchinsky and Rajeev Shah.
The amendment details recent open-market purchases by RA Capital Healthcare Fund, including multi-million share buys on March 26, 27, and 30, 2026 at weighted-average prices between $6.06 and $6.50 per share, funded with the fund’s working capital. Certain shares are issuable upon exercise of pre-funded warrants and stock options.
Wave Life Sciences Ltd. reported significant open-market buying by entities associated with RA Capital. RA Capital Healthcare Fund LP, advised by RA Capital Management, L.P., purchased a total of 8,772,496 ordinary shares in open-market transactions between March 26 and March 30, 2026 at prices around $6.06–$6.50 per share. Following these purchases, the Fund’s indirect holdings reached 26,975,505 ordinary shares, with an additional 28,815 shares linked to previously reported RSU awards held by Dr. Peter Kolchinsky for the benefit of the Fund. The Adviser, its general partner, the Fund, Dr. Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.